Femoston as a hormone replacement therapy for ovarian failure
- 作者: Repinа M.1, Zinina T.1, Korzo T.1
-
隶属关系:
- St. Petersburg Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
- 期: 卷 48, 编号 1 (1999)
- 页面: 94-100
- 栏目: Viewpoint
- URL: https://journals.rcsi.science/jowd/article/view/88690
- DOI: https://doi.org/10.17816/JOWD88690
- ID: 88690
如何引用文章
全文:
详细
The article presents the results of a number of hemostasis parameters (coagulation, vascular and thrombocytic) and lipoprotein spectra, including apo A-1 and apo B100 apoproteins against the background of hormone replacement treatment with Femostone (Solvay, Germany). The results were compared taking into account menstrual cycle phases in perimenopausal patients (with a preserved cycle) and conditional estrogenic, progestagenic phases of Femostone administration. The advantages of the progestagen didrogesterone included in the drug in its effect on the lipid spectrum, apoproteins and some parameters of vascular thrombocyte hemostasis are shown.
作者简介
M. Repinа
St. Petersburg Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
编辑信件的主要联系方式.
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg
T. Zinina
St. Petersburg Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg
T. Korzo
St. Petersburg Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg